ASANA BIOSCIENCES ANNOUNCES A PHASE II TRIAL IN PATIENTS WITH MF

Asana BioSciences announces a Phase II study in patients with myelofibrosis is in progress in the US.

Study name:  ASN002-101 – PHase 1/2, open-label, uncontrolled, multiple-dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of asn002 in relapsed/refractory lymphoma, myelofibrosis, chronic lymphocytic leukemia and advanced solid tumors

https://clinicaltrials.gov/ct2/show/NCT02440685?term=Asana&draw=1&rank=5